Our Clinical Trials

AML

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myloid Leukemia in Complete Remission.

A Phase IIb, randomized, double-blind, placebo-controlled, low-dose cytarabine and Lintuzumab In comparison with the low-dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML.


Biomarker Expression

A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients.


Bladder

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Bladder Tumors.


Breast

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.

A Phase II, An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis.

A Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide.

Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) who have received prior HER2 Regimens for MBC.

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease.

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer.

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with reviously Treated Diffuse Large B-Cell Lymphoma.

Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease

A Phase 1b/2 Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase (PEGPH20) versus Eribulin Mesylate Alone in Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Randomized phase II neoadjuvant trastuzumab and / or lapatinib plus chemotherapy (sequential FEC75 and paclitaxel) in women with ErbB2 (HER2) overexpressinginvasive breast cancer trial.

A Phase III, randomized, open-label Versus Neratinib lapatinib plus capecitabine for the treatment of ErbB-2 positive metastatic or locally advanced breast cancer.

A phase III randomized, double-blind, controlled trial with placebo to evaluate the efficacy and safety of pertuzumab plus trastuzumab + docetaxel vs. Placebo + trastuzumab + docetaxel in HER2-positive breast cancer previously untreated metastatic.

A multicenter, international study open - label, two-arm, Phase III trial of Avastin in adjuvant "triple negative" breast cancer.

Randomized phase III study of sunitinib in combination with capecitabine compared with capecitabine in breast cancer patients previously treated Or metastatic An international, randomized, double-blind, placebo-controlled, Phase II AMG 479 with exemestane or fulvestrant in postmenopausal women with hormone receptor positive breast cancer locally advanced: • randomized studies evaluating AMG 479.

An observational study of treatment patterns of the results of safety metastatic or locally advanced breast cancer.

A randomized, multicenter, phase III open-label study of the efficacy and safety of trastuzumab-MCC-DM1 VS. Lapatinib and capecitabine in patients with HER2-positive breast cancer locally advanced or metastatic who have received prior trastuzumab-based therapy.

A prospective, randomized, double-blind, stratified, multi-Trial 2 arms of the continued efficacy and safety of Zometa ® (every 4 weeks versus every 12 weeks) in patients with documented bone metastases from breast cancer.

A phase II, randomized, open-label bosutinib administered in combination with letrozole versus letrozole alone as first-line therapy in postmenopausal women with locally advanced or metastatic ER + / PGR + / erbB2- Breast Cancer.

An observational study of treatment patterns and safety outcomes for metastatic breast cancer or locally recurrent.

A phase II, double-blind, randomized, placebo-controlled study of ACE-011 for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer.

A Phase II, multicenter, open-label, randomized study of YM155 and docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer protocol for the Phase II of YM155.

A, open, randomized, phase III taxane based chemotherapy with lapatinib and trastuzumab as first-line treatment for women with metastatic breast cancer HER2 / neu positive.

A, 3 randomized, multicenter, phase III study to evaluate the efficacy and safety of T-DM1 combined with pertuzumab and T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab) arm, versus Herceptin plus-taxane combination as first-line therapy in progressive or recurrent breast cancer locally advanced or metastatic HER2-positive (MBC).

A Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of KW-2450 in combination with letrozole and lapatinib in patients with advanced or metastatic breast cancer whose tumors overexpress HER2.

Observational cohort study of treatment patterns and outcomes in patients with HER2 positive (HER2 +) metastatic breast cancer.

A study of more Neratinib capecitabine versus lapatinib plus capecitabine in patients with HER2 + HER2 + metastatic cancer who have received two or more HER2-Directed regimes earlier in metastatic disease (NALA).

Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA).

A Phase 2, Multicenter, open-label study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer.

Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.

A Phase II, An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis.


CLL

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy.

Screening Protocol to Determine High-risk Cytogenetic Features in Patients with Previously-treated CLL that may be Eligible for TG Therapeutics Trial UTX-IB-301.

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor

A Phase III, multicenter, randomized, open, parallel-group study of the efficacy and safety of lenalidomide (Revlimid ®) versus chlorambucil as first-line treatment for elderly patients treated Mobile B- previously with chronic lymphocytic leukemia

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

A Phase III Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)


CML

An open label, randomized (2:1) Phase 2B study of Dasatinib vs Imatinib in patients with chronic phase chronic myeloid leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg imatinib


Colorectal

A multicenter, open-label, randomized, phase II study to evaluate the efficacy and safety of NKTR-102 (PEG-irinotecan) versus irinotecan in patients with second line, irinotecan- Naïve, -mutante KRAS metastatic colorectal cancer (mCRC)

Phase 1b / 2 Study of AMG 655 in combination with modified FOLFOX6 and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer.

Locally advanced observational study of Bevacizumab (Avastin) in combination with chemotherapy for the treatment of metastatic colorectal cancer or locally advanced unresectable or metastatic non-small cell lung metastatic (except predominant histology squamous) cells. Locally advanced or metastatic CRC unresectable locally advanced or metastatic NSCLC

A Randomized Phase 2 Study 7 on / 7 capecitabine in combination with irinotecan or oxaliplatin short duration and bevacizumab either short-lived as first-line treatment for patients with metastatic colorectal cancer.

Comparison of the performance of the Epi proColon test and fecal immunochemical Post colonoscopy in patients with colorectal cancer and colonoscopy in subjects Pre-Eligible Population Screening Guidance.

A Phase 3 open-label, randomized, multicenter Print PGG ® in combination with cetuximab (Erbitux ®) in patients with recurrent or progressive type KRAS colorectal cancer Wild.

A Phase III, multicenter, open, randomized, pivotal trial of Vera MABp1 ™ human monoclonal antibody in patients with metastatic colorectal cancer who are refractory to standard therapy.


Gastrointestinal

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

A double-blind, randomized, multicenter Phase III study of Avastin in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin as first-line treatment in patients with advanced gastric cancer.

A database of observation to obtain data on variations in the current diagnostic and therapeutic management of patients with GIST in a variety of practice areas.

A randomized, open-label, multicenter Phase IIIb Comparison study of two dosage regimens Trastuzumab, each in combination with cisplatin / capecitabine chemotherapy as first-line treatment in patients with HER2-positive metastatic gastric or Gastro Junction Adenocarcinoma -esofágico who have not received prior treatment for metastatic disease.


HCC

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment.

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment.


Head and Neck

A randomized, double-blind, Phase 2 study of cetuximab safety, ImClone against Boehringer Ingelheim With manufacturing processes, in combination with cisplatin or carboplatin and 5-fluorouracil in the first-line treatment of patients with recurrent locoregional and / or metastatic squamous cell carcinoma of head and neck.

A multi-center, single-arm, global, Phase II study to determine the efficacy and safety of MEDI4736 monotherapy in the treatment of patients with recurrent or metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with a platinum-containing regimen for recurrent or metastatic disease.

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in combination with Tremelimumab vs Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.


Hematology

A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia.

A Phase 3 Study of ALXN1210 versus Eculizumab in Patients With Paroxysmal Notcurnal Hemoglobinuria.

A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

A Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)


Lung

A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer.

A Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene.

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations.

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer.

A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies.

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

A Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer Receiving Etoposide and Carboplatin Chemotherapy.

A Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphomide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line

Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

A Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion

A Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

A Phase III, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy of Avastin in combination with Tarceva (erlotinib) compared with Tarceva alone for the treatment of metastatic non-small cell lung Advanced ( NSCLC) after failure of standard first-line chemotherapy.

Observational study to evaluate the impact of ethnicity in patients being treated with ALIMTA in second-line non-small cell lung cancer.

A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of darbepoetin alfa administered 500 mg every 3 weeks (Q3W) in anemic subjects with advanced stage non-small lung cancer treated with multiple chemotherapy cycle.

Paclitaxel poliglumex (CT-2103) / carboplatin versus paclitaxel / carboplatin for the treatment of advanced non-small without prior chemotherapy (NSCLC) in women with estradiol> 30 pg lung cancer / ml.

Phase II, open-label trial of PF-00299804 in treating advanced lung adenocarcinoma in never or light former smokers.

A Randomized Phase 2 Study with or without erlotinib in previously treated patients ARQ197 w / locally advanced or metastatic NSCLC Non-small cell lung cancer locally advanced or metastatic (excluding predominant squamous cell histology) an observational study of Bevacizumab (Avastin) in combination with chemotherapy for the treatment of metastatic colorectal cancer or locally advanced unresectable: • observational study of Avastin.

A small non-randomized phase II lung maintenance temozolomide versus observation in response stable or Stage IIIB / IV cell cancer patients.

Multicenter, randomized, double-blind, Phase III to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed treatment compared with placebo plus standard pemetrexed in patients with stage IIIB / IV or recurrent non-small cell lung cancer after failure of first-line chemotherapy.

A randomized, double-blind, placebo-controlled study of the safety and efficacy of farletuzumab in combination with carboplatin and paclitaxel or docetaxel followed pemetrexed in patients not previously treated with chemotherapy Stage IV lung adenocarcinoma wild-type EGFR.

A controlled, double-blind, multicenter, randomized, phase II study of bevacizumab in stage small cell lung cancer previously untreated.

A randomized, double-blind, parallel, three-arm, multicenter Phase II trial evaluating the efficacy and safety of ipilimumab (BMS-734016) in combination with Taxol / Paraplatin (paclitaxel / carboplatin) compared to Taxol / Paraplatin alone in previously untreated subjects with lung cancer.

Evaluating sunitinib: Phase III randomized, double-blind, controlled study of efficacy and safety of sunitinib in patients with non small cell lung cancer advanced / metastatic cells treated with erlotinib or SUTENT Trial.

Phase III, randomized, placebo-controlled, double-blind cancer vaccine "Stimuvax (L-BLP25 or BLP25 liposome vaccine) in patients with NSCLC with unresectable stage III disease" or START Trial.

2 randomized phase Ezatiostat Hydrochloride (TELINTRA TLK199 tablets) for the treatment of chemotherapy-induced neutropenia in cancer patients with non-small study cell lung locally advanced or metastatic receiving first-line chemotherapy.

A randomized phase 2 trial PF-00299804 Versus erlotinib for the treatment of metastatic non-small cell lung Advanced after failure of at least one prior chemotherapy regimen.

A randomized, double-blind, placebo-controlled, Phase IIIb trial comparing bevacizumab therapy with or without erlotinib After completion of chemotherapy with bevacizumab for the first-line treatment of Non-squamous non- small cell locally advanced or metastatic cell lung cancer.

A, open, randomized, phase 2 trial of paclitaxel / carboplatin with or without Bavituximab in patients previously untreated NSCLC no locally advanced or metastatic squamous.

Lung 3, A, open, randomized, phase III study of BIBW 2992 compared with chemotherapy as first-line treatment for patients with stage IIIB or IV lung adenocarcinoma Hosting an activating EGFR mutation.

A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of darbepoetin alfa administered 500 mg every 3 weeks (Q3W) stadium in anemic patients with non-small lung cancer Advance cells that receive multiple chemotherapy cycle.

A random phase, double-blind, placebo-controlled 2 Trial Bavituximab plus docetaxel in previously treated patients with locally advanced or metastatic non-squamous.

Phase 2, double-blind, placebo-controlled IPI-504 and docetaxel in previously treated patients with non-small stage IIIB or IV lung cancer cells.

AT13387 HSP90 inhibitor alone and in combination with crizotinib in the treatment of non-small cell lung cancer (NSCLC).

A multicenter, open-label Phase 2 study of the safety and activity of Lenvatinib (E7080) in patients with adenocarcinoma KIF5B-RET-positive lung.

An open label, randomized, phase IIIb trial evaluation of the efficacy and safety of the Standard of Care + / - Avastin treatment continues beyond disease progression in patients with non-squamous non-small lung cancer advanced (NSCLC) After first-line treatment with Avastin plus chemotherapy has Douublet A Platinum (MO22097).

A stamp expanded access program open afatinib (BIBW 2992) for patients with NSCLC locally advanced or metastatic (NSCLC) harboring the EGFR mutation (s).

A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer.

A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer.

A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers.

A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent.

A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy.

A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer.

A Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene.


Lymphoma

A Phase Ib, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma.

A Phase 3 Randomized, Double-Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patients with CD20-positive, Low Tumor Burden, Follicular Lymphoma.

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.

A Phase 3 Randomized, Double-Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patients with CD20-positive, Low Tumor Burden, Follicular Lymphoma

A Phase Ib, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

A Phase IIb, randomized, double-blind, placebo-controlled, low-dose cytarabine and Lintuzumab In comparison with the low-dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML.

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY 80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas.

A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine with or without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma.


MDS

2 randomized phase study comparing two doses lists Ezatiostat Hydrochloride (TELINTRA, TLK199 Tablets) in low to intermediate-1 risk myelodysplastic syndrome (MDS).


Multiple Myeloma

Directed Bone Marker Dosage Zometa (zoledronic acid) for the prevention of bone complications in patients with advanced multiple myeloma.

Factors determining overall survival in patients with multiple myeloma treated with Zoledronic Acid.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for newly diagnosed patients and multiple myeloma.

Randomized Phase IIIb of three treatment regimens in patients with previously untreated multiple myeloma who are not considered candidates for high-dose chemotherapy and autologous stem cell transplantation: VELCADE (bortezomib), thalidomide dexamethasone (VTD) versus VELCADE and dexamethasone (VD) compared to VELCADE, melphalan and prednisone (VMP).

Prospective Evaluation of Research in Multiple Myeloma: an observational evaluation (Preamble).

An Observational Evaluation.

A Phase 2, Multicenter, Single-Arm, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide Plus Dexamethasone in the Second-Line Setting.

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma.


Nausea and Vomiting

Multicenter phase III, randomized, double-blind, double-dummy, parallel group active in the efficacy and safety of oral Netupitant control is given in combination with palonosetron and dexamethasone compared to palonosetron and oral dexamethasone for the prevention of nausea and vomiting in cancer patients with chemotherapy emetogenic Receivingmoderately.

A phase 3, multicenter, randomized, double-blind, active-controlled safety and efficacy of Rolapitant for the Prevention of chemotherapy nausea and vomiting induced by chemotherapy (CINV) in patients receiving highly emetogenic chemotherapy (HEC).

A phase 3, multicenter, randomized, double-blind, active-controlled safety and efficacy of Rolapitant for the Prevention of chemotherapy nausea and vomiting induced by chemotherapy (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).


Ovarian

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation.

A Study of Physician’s Choice Chemotherapy Weekly Paclitaxel (PCC) or Pegylated Liposomal Doxorubicin (PLD) Plus Bevacizumab and CA4P versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

Phase IIb study evaluate the safety and efficacy of TXA127 in reducing the incidence and severity of thrombocytopenia in patients receiving combination therapy of gemcitabine and platinum per ovary, fallopian tube or peritoneal carcinoma.

Randomized phase II trial Investigate liposomal doxorubicin with or without anti-derived growth factor platelet receptor alpha (PDGFR) monoclonal antibody IMC-3G3.

An open-label randomized crossover bioequivalence study and safety of doxorubicin hydrochloride injection liposome formulations in patients with advanced ovarian carcinoma.

A double-blind, randomized, placebo-controlled HVAC (Augologous dendritic cells pulsed with recombinant human fusion protein [mucin 1-glutathione S-Transferqase] Along with rusty polymannose) as maintenance therapy in patients with epithelial ovarian Cancer (EOC) in complete remission after first-line chemotherapy.

A Phase 1/2a Evaluation of the Safety and Efficacy of AL3818 to Standard Platinum Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Cancer.


Pancreatic

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.

A, open, randomized, phase 2 trial of gemcitabine with or without Bavituximab in patients with pancreatic cancer in previously untreated stage IV.

A Randomized Phase 2 Study of Efficacy and Safety Ruxolitinib in combination with capecitabine for patients with recurrent or refractory treatment of metastatic pancreatic cancer.

A randomized Security and exploratory efficacy study of Kanglaite injection Gemcitabine Plus (G + K) versus gemcitabine in patients with advanced pancreatic cancer.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine).

Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study).

A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer.

A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy.


Prostate

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate the Serum Testosterone Level in Patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate 500mg (4 x 125mg QD) with Methylprednisolone (4mg BID) as Compared to Zytiga® (4 x 250mg QD) with Prednisone (5mg BID).

Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

Asymptomatic castration resistant prostate cancer (CRPC) metastatic - Phase II randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of ABR-215050 in asymptomatic patients with metastatic prostate cancer resistant castration.

A Randomized, Double - Blind, Multicenter Study denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer.

Prospective observational study of Survival, treatment patterns, disease and economic outcomes in patients with refractory metastatic to cancer castration prostate (CRPC) with progression during or after first - line docetaxel - based regime.

A randomized phase III study comparing standard first-line docetaxel / prednisone docetaxel / prednisone in combination with custirsen (OGX-011) in men with metastatic prostate cancer resistant to castration.

Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.


Renal Cell Carcinoma

A study of pazopanib versus sunitinib in the treatment of patients with renal cell carcinoma locally advanced and / or metastatic.

Axitinib (AG-013736) as a second-line therapy for metastatic renal cell.


Sarcoma

A pivotal trial to determine the efficacy and safety of AP23573 when given as maintenance treatment of patients with soft tissue or bone sarcomas metastatic.


Solid Tumors

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Mild, Moderate, and Severe Renal Impairment.

A Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes.

A Phase I, Open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors.

A phase Ib, single arm, open-label clinical trial to evaluate QTc and Drug - Interaction Drug Trastuzumab carboplatin in the presence of docetaxel in patients with HER2-positive metastatic or inoperable locally advanced cancer.

A study to assess the relationship between treatment with cetuximab and corrected QT (QTc) interval changes in patients with advanced solid tumors other than brain tumors A phase 1 study to evaluate the effect of NKTR-102 for injection (ETITRNOTECAN PEGOL) on the QT/QTC interval in patients with advanced OR metastatic solid tumors.

An Open-label, multicenter, extension study of NKTR-102 in subjects previously enrolled in NKTR-102 Studies.

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors.


Specimen Collection

An Observational Study to Collect Specimens for Future Scientific Research

Specimen Collection from Individuals diagnosed with Late State (Stage III or IV) Non-Small Cell Lung Carcinoma


Denotes Active Clinical Trial.

1700 E. Cesar Chavez Ave. Suite 3750
Los Angeles
CA
90033
United States
323-284-4077